Hypertension Clinical Pearls: We re treating more than a number

Similar documents
Hypertension (JNC-8)

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)

Cardiac Medications At A Glance

Antihypertensive Agents

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg

8/19/2016. No Conflicts. I struggled with everything cardiac in nursing school.

Preventing and Managing High Blood Pressure

What in the World is Functional Medicine?

Management of Hypertension

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

Cardiovascular Clinical Practice Guideline Pilot Implementation

Heart Failure Clinician Guide JANUARY 2018

Difficult to Treat Hypertension

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure.

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Adult Blood Pressure Clinician Guide June 2018

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

Heart Failure Clinician Guide JANUARY 2016

Hypertension Management - Summary

Diabetes and a Healthy Heart. Meeting 6. Welcome! Glucose. Balance Makes a Difference! Medicine Helps with. Glucose. Balance!

New Hypertension Guidelines: How Lower Blood Pressure Targets Affect Medication Safety

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension Update Clinical Controversies Regarding Age and Race

Guideline-Directed Medical Therapy

LESSON ASSIGNMENT. After completing this lesson you will be able to:

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%

Hypertension: Update

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Section 3, Lecture 2

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Network Hypertension Algorithm

Physician/Clinic Collaborative Practice Agreement

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

Contemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Medications and Falls Part 1

Some Facts. Medications and Falls Part 1. Centers for Disease Control (CDC) Falls Statistics for Older Adults ( 65yrs) 11/27/2018

PassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?

HEART FAILURE: PHARMACOTHERAPY UPDATE

Value-Based Drug List for ABCs of Diabetes

MEDICATION FACT SHEET

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR

Top 200 Section 4. Cardiovascular Drugs

Codes for a Medicare claims-based model to predict LVEF class- User Guide

Guide to the New Hypertension Guidelines

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Hypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut

2014 HYPERTENSION GUIDELINES

8/20/2017. No Conflicts. I struggled with everything cardiac in nursing school. Review background and definitions of hypertension with

Guide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital

Hypertension Controversies: SPRINTing to New Goals

Treating Hypertension in Individuals with Diabetes

Balanced information for better care. Heart failure: Managing risk and improving patient outcomes

Annual Review of Antihypertensives - Fiscal Year 2009

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7

New classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

Antihypertensive drugs: I. Thiazide and other diuretics:

Updates in Cardiovascular Recommendations for Diabetic Patients

Heart Disease and Prevention PRESENTED BY: DOTTIE CRAIG NP- C, JANE ARCHER NP-C, KATHY DAPPER RN, NICCI FRAVEL RN

TREATMENT OF HYPERTENSION

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

Living with Congestive Heart Failure: A Guide to a Healthy Heart

Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Clinical Teach-Back Cards

sympatholytics sympatholytics sympatholytics

2017 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults

What s at the Heart of the Matter?

Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN

Hypertension (HTN) Lecture Note

HEART FAILURE KEEPING YOUR PATIENT AT HOME

CONCORD INTERNAL & PULMONARY MEDICINE CONGESTIVE HEART FAILURE PROTOCOL. Douglas G. Kelling, Jr., MD & C. Gismondi-Eagan, MD, FACP

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Factors Involved in Poor Control of Risk Factors

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

α 1 receptor smooth muscle activation

Summary/Key Points Introduction

Comparison of Oral Beta-Blockers

Treatment of Hypertension

Blood Pressure Management in Acute Ischemic Stroke

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

CARDIAC IMAGING QUESTIONNAIRE

Treatment of Essential Hypertension

Transcription:

Hypertension Clinical Pearls: We re treating more than a number Emily Ashjian, PharmD, BCPS, BCACP February 2017

Learning Objectives Review blood pressure goals and differences between treatment guidelines Discuss treatment strategies for patients with resistant hypertension Develop appropriate treatment regimens for hypertension based on patient specific factors and co-morbidities

Meet JS 67 year old male referred to the ambulatory care clinical pharmacist for management of resistant hypertension. Previously presented as a new patient 3 weeks ago after seeking care in the ED for a gout flare which has since resolved. PMH: HTN, T2DM, HFrEF (EF 36%), AF, STEMI (3/2015), gout, migraines, Stage 3 CKD Social hx: -EtOH: 2-3 drinks per night -Tobacco: ½ ppd (recently decreased from 1ppd) Allergies: ACE-Is tried several in the past (cough) Vitals: BP: 164/94 mmhg, HR 82 Weight: 170 lbs BMI: 32.5

Meet JS Medications: allopurinol 100 mg daily atenolol 25 mg daily aspirin 81 mg daily atorvastatin 40 mg daily apixaban 5 mg twice daily hydrochlorothiazide12.5 mg daily clonidine 0.1 mg daily furosemide 20 mg daily glipizide XL 10 mg daily ibuprofen 400 mg twice daily as needed losartan 25 mg daily metformin 1000 mg twice daily potassium chloride 20 meq daily tramadol 50 mg twice daily as needed Labs 2/2/17 Na 135 meq/l K 4.2 meq/l BUN 29 mg/dl SCr 1.4 g/dl Glucose 179 mg/dl Total Cholesterol 211 mg/dl HDL 42 mg/dl TG 250 mg/dl LDL-C 119 mg/dl Urine microal/cr 19 mg/g egfr HbA1c 8.2% Uric acid 6.7 CrCl 59 ml/min/1.73 m2 ~56 ml/min

What is Hypertension (HTN)? 2 or more blood pressure readings 140/90 mmhg 2 or more clinical encounters Systolic blood pressure 140 mmhg Diastolic blood pressure 90 mmhg Taking antihypertensive medications

Resistant HTN BP 140/90 mmhg while using optimally dosed medications from 3 different classes including a diuretic Taking 4 or more antihypertensives regardless of BP Circulation 2008;117:e510-e526.

Etiology Primary Hypertension (90-95%) Idiopathic Secondary Hypertension (5-10%) Chronic kidney disease Cushing s syndrome or excess glucocorticoid states Drug-induced or drug-related Obstructive uropathy Pheochromocytoma Primary aldosteronism or other mineralocorticoid excess Renovascular disease Sleep apnea Thyroid or parathyroid disease Circulation 2008;117:e510-e526.

Set blood pressure goal JAMA. 2014;311:507-520.

Comparison of Blood Pressure Goals HTN: Hypertension. CV: Cardiovascular. ASH/ISH: American Society of Hypertension/International Society of Hypertension. CHEP: Canadian Hypertension Education Program. ESH/ESC: European Society of Hypertension/European Society of Cardiology. ADA: American Diabetes Association. ACC/AHA: American College of Cardiology/American Heart Association. KDIGO: Kidney Disease: Improving Global Outcomes. Adapted from: ACCP Pharmacotherapy Self-Assessment Program 2016. See last slide for complete citations.

ACCORD N Engl J Med 2010;362:1575-1585.

Lifestyle changes Hypertension. 2008;51:1403-1419. Hypertension. 2003;42:1206-1252.

Select Medications JAMA. 2014;311:507-520.

Back to JS Medications: allopurinol 100 mg daily atenolol 25 mg daily aspirin 81 mg daily atorvastatin 40 mg daily apixaban 5 mg twice daily hydrochlorothiazide 12.5 mg daily clonidine 0.1 mg daily furosemide 20 mg daily glipizide XL 10 mg daily ibuprofen 400 mg twice daily as needed losartan 25 mg daily metformin 1000 mg twice daily potassium chloride 20 meq daily tramadol 50 mg twice daily as needed Problem List: HTN T2DM HF AF STEMI (3/2015) Gout Migraines Stage 3 CKD

Back to JS Medications by indication: HTN: atenolol 25 mg daily, hydrochlorothiazide 12.5 mg daily, clonidine 0.1 mg daily, furosemide 20 mg daily, losartan 25 mg daily HFrEF: atenolol 25 mg daily, furosemide 20 mg daily, losartan 25 mg daily STEMI: atenolol 25 mg daily, aspirin 81 mg daily, atorvastatin 40 mg daily, losartan 25 mg daily AF: apixaban 5 mg twice daily, atenolol 25 mg daily T2DM: metformin 1000 mg twice daily, glipizide XL 10 mg daily Gout: allopurinol 100 mg daily Migraines: tramadol 50 mg twice daily as needed No listed problem: ibuprofen 400 mg twice daily as needed, potassium chloride 20 meq daily

Cardiovascular Conditions Condition Angina History of Myocardial Infarction Heart Failure with reduced Ejection Fraction (HFrEF) Disease Specific Medication Beta blocker ACE-I if LV dysfunction Beta blocker ACE-I Beta blocker ACE-I Aldosterone antagonist Relatively Contraindicated Non-DHP CCB if reduced LVEF -- -- Non-DHP calcium channel blocker Alpha blocker Notes -ARB if ACE-I not tolerated -Beta blockers should be used in low dosage and slowly titrated -Hydralazine + isosorbide dinitrate if ACE-I/ARB not tolerated Adapted from: UMHS FGP Guideline: Essential Hypertension 2014.

Post-Myocardial Infarction Beta blocker Oral beta blockers should be continued during and after hospitalization for all patients with STEMI and no contraindications to their use Start and continue for 3 years for all patients with history of MI or ACS (reasonable to continue as chronic therapy after 3 years) Consider as chronic therapy for all other patients with coronary or vascular disease ACE-I Initiate within 24 hours of anterior wall STEMI, in patients presenting with s/sxs of HF, and those with LVEF 40% unless contraindicated Continue indefinitely in those with LVEF 40%, HTN, DM, or CKD ARB Alternative in those unable to tolerate ACE-I Aldosterone Antagonists For those already receiving an ACE-I + beta blocker with LVEF 40% and either symptomatic HF or DM Circulation. 2013;127:529-55.

Heart Failure HFrEF EF 40% ACE-I Evidence based beta-blocker (carvedilol, metoprolol succinate, bisoprolol) Class II-IV + LVEF < 35%: spironolactone HFrEF (symptomatic) + LVEF < 40% after acute MI: spironolactone HFpEF EF 50% Blood pressure control Circulation 2013;133:e240-327.

HFrEF: ACE-I Recommended in all patients with symptomatic HFrEF (reduce mortality and heart failure hospitalization) Generic Brand Initial dose Target dose Captopril Capoten 6.25 mg TID 50 mg TID Enalapril Vasotec 2.5 mg BID 10-20 mg BID Fosinopril Monopril 5-10 mg daily 40 mg daily Lisinopril Zestril, Prinivil 2.5-5 mg daily 20-40 mg daily Perindopril Aceon 2 mg daily 8-16 mg daily Quinapril Accupril 5 mg BID 20 mg BID Ramipril Altace 1.25-2.5 mg daily 10 mg daily Trandolapril Mavik 1 mg daily 4 mg daily Circulation 2013;133:e240-327.

HFrEF: ARBs Recommended in patients with symptomatic HFrEF unable to tolerate an ACE-I (reduce mortality and heart failure hospitalization) Generic Brand Initial dose Target dose Candesartan Atacand 4-8 mg daily 32 mg daily Losartan Cozaar 25-50 mg daily 50-150 mg daily Valsartan Diovan 20-40 mg BID 160 mg BID Avoid combining an ACE-I + ARB Circulation 2013;133:e240-327.

HFrEF: Beta blockers Recommended in patients with symptomatic HFrEF (reduce mortality and heart failure hospitalizations) Generic Brand Initial dose Target dose Bisoprolol Zebeta 1.25 mg daily 10 mg daily Carvedilol Coreg 3.125 mg BID 25-50 mg BID Carvedilol Coreg CR 10 mg daily 80 mg daily Metoprolol succinate Toprol XL 12.5-25 mg daily 200 mg daily Circulation 2013;133:e240-327.

HFrEF: Mineralocorticoid antagonists Recommended in patients with symptomatic HFrEF (reduce mortality and heart failure hospitalizations) Generic Brand Initial dose Target dose Spironolactone Aldactone 12.5-25 mg daily 25 mg daily Eplerenone Inspra 25 mg daily 50 mg daily Dosing and titration based on renal function: Estimated CrCl 30-49 ml/min 50 ml/min Eplerenone Spironolactone Eplerenone Spironolactone Initial dose (K<5) Maintenance (K<5) 25 mg every other day 12.5 mg daily or every other day 25 mg daily 12.5-25 mg daily 25 mg daily 12-25 mg daily 50 mg daily 25 mg daily or BID Circulation 2013;133:e240-327.

HFrEF: Other vasodilators Recommended in patients with symptomatic HFrEF (reduce HF hospitalizations) Generic Brand Initial dose Target dose Hydralazine/ isosorbide dinitrate BiDil 37.5/20 mg TID 75/40 mg TID Hydralazine Apresoline 25-50 mg TID 100 mg TID Isosorbide dinitrate Isordil 20-30 mg TID 40 mg TID Circulation 2013;133:e240-327.

HFrEF: Loop Diuretics Generic Brand Initial dose Furosemide Lasix 20-40 mg daily or twice daily Torsemide Demadex 10-20 mg daily Bumetanide Bumex 0.5-1 mg daily or twice daily Conversion (oral): 40 mg furosemide: 20 mg torsemide: 1 mg bumetanide Circulation 2013;133:e240-327.

Diuretics: Sites of action

Thiazide/Thiazide-type Diuretics Formulations & Dosing Generic Brand Dosing (mg) Frequency Chlorthalidone Hygroton 12.5-25 Once daily Hydrochlorothiazide Microzide 12.5-50 Once daily Indapamide Lozol 1.25-2.5 Once daily Metolazone Zaroxolyn 2.5-5 Once daily

Cardiovascular Conditions Condition Supraventricular tachycardia (Atrial Fibrillation) Bradycardia Heart block Disease Specific Medication Beta blocker Non-DHP CCB Relatively Contraindicated -- Beta blocker Non-DHP CCB α2-agonist Adapted from: UMHS FGP Guideline: Essential Hypertension 2014.

β-blockers Mechanism of Action http://www.cardiachealth.org/sites/default/files/images/stories/medications/betablocker.bmp

β-blockers Cardioselective atenolol betaxolol bisoprolol metoprolol tartrate metoprolol succinate Tenormin Kerlone Zebeta Lopressor Toprol Mixed (α and non-selective β effects) carvedilol labetalol Coreg Trandate Intrinsic sympathomimetic activity acebutolol carteolol penbutolol pindolol nadolol propranolol propranolol long-acting Sectral Cartrol Levatol Visken Non-selective timolol Corgard Inderal Inderal LA blocadren

Calcium Channel Blockers Dihydropyridines amlodipine Norvasc felodipine Plendil isradipine DynaCirc CR nicardipine Cardene nifedipine Procardia nisoldipine Sular Non-dihydropyridines diltiazem verapamil Cardizem, Dilacor, Taztia, Tiazac Calan, Isoptin, Verelan

Calcium Channel Blockers Mechanism of Action Calcium Channel Blocker Dihydropyridine Calcium channels on vascular smooth muscle Site of inhibition Calcium channels of cardiac conduction system Non-dihydropyridine

Back to JS Medications by indication: HTN: atenolol 25 mg daily, hydrochlorothiazide12.5 mg daily, clonidine 0.1 mg daily, furosemide 20 mg daily, losartan 25 mg daily HFrEF: atenolol 25 mg daily, furosemide 20 mg daily, losartan 25 mg daily STEMI: atenolol 25 mg daily, aspirin 81 mg daily, atorvastatin 40 mg daily, losartan 25 mg daily AF: apixaban 5 mg twice daily, atenolol 25 mg daily T2DM: metformin 1000 mg twice daily, glipizide XL 10 mg daily Gout: allopurinol 100 mg daily Migraines: sumatriptan 100 mg as needed No listed problem: ibuprofen 400 mg twice daily as needed, potassium chloride 20 meq daily

Endocrine/Renal Condition Disease Specific Medication Relatively Contraindicated Notes Diabetes Mellitus ACE-I or ARB DHP CCBs, thiazides may be used if uma/cr WNL Chronic Kidney Disease Gout ACE-I DHP CCB (alone) -ARB if ACE-I not tolerated -Consider spironolactone or eplerenone if proteinuria -Loop diuretic if egfr < 30 Losartan (uricosuric) -Thiazides may contribute to gout Adapted from: UMHS FGP Guideline: Essential Hypertension 2014.

Central Nervous System/Psychiatric Condition Disease Specific Medication Relatively Contraindicated Notes Headaches Beta blocker Non-DHP CCB -Propranolol, timolol for migraine prophylaxis -Verapamil for cluster headache prophylaxis Essential tremor Beta blocker Concurrent lithium use Beta blocker Non-DHP CCB DHP CCB Diuretic ACEI ARB -Thiazides may increase lithium level by 25-40%; ACE- Is, ARBs may also increase lithium concentrations -Potassium sparing diuretics have minor effects PTSD Alpha blocker (prazosin) Crosses blood brain barrier PTSD associated nightmares Adapted from: UMHS FGP Guideline: Essential Hypertension 2014.

Genitourinary Conditions Condition Disease Specific Medication Relatively Contraindicated Notes Bilateral renal artery stenosis Beta blocker DHP CCB ACE-I ARB Impotence ACE-I or ARB DHP CCB Avoid beta blockers Adapted from: UMHS FGP Guideline: Essential Hypertension 2014.

Special Populations/Other Condition Disease Specific Medication Relatively Contraindicated Notes Pregnancy Methyldopa (preferred) Labetalol, hydralazine, CCB, beta blockers (except atenolol, propranolol) Atenolol Propranolol ACE-I, ARB are absolutely contraindicated Patients taking cyclosporine DHP CCB Beta blocker Reactive Airway Diseases If beta blockers used, start low and slowly titrate Adapted from: UMHS FGP Guideline: Essential Hypertension 2014.

Back to JS Medications by indication: HTN: carvedilol 12.5 mg twice daily, furosemide 20 mg daily, losartan 50 mg twice daily, spironolactone 12.5 mg daily HFrEF: carvedilol 12.5 mg twice daily, furosemide 20 mg daily, losartan 50 mg twice daily, spironolactone 12.5 mg daily STEMI: carvedilol 12.5 mg twice daily, aspirin 81 mg daily, atorvastatin 40 mg daily, losartan 50 mg twice daily, spironolactone 12.5 mg daily AF: apixaban 5 mg twice daily, carvedilol 12.5 mg twice daily T2DM: metformin 1000 mg twice daily, glipizide XL 10 mg daily Gout: allopurinol 100 mg daily Migraines: tramadol 50 mg twice daily as needed

How low is too low? SBP is a stronger predictor of cardiovascular disease than DBP in adults age > 50 Pulse pressure = SBP-DBP Increased pulse pressure reflects degree of artherosclerotic disease in elderly; measure of increased arterial stiffness Caution with diastolic blood pressure less than 60 mmhg Lancet. 2002;360:1903-13.

24 hour blood pressures N Engl J Med 2006;354:2368-74.

Bedtime Dosing of BP Medication(s) Blood pressure follows a circadian rhythm Non-dippers have a higher risk of cardiovascular events Evidence that moving at least one BP med to bedtime improves BP control, reduces the prevalence of non-dipping, and lowers cardiovascular morbidity and mortality Considerations: Impact on patient adherence Diuretics at bedtime nocturia Diabetes Care 2011; 34:1270-76. J Clin Hypertension 2014;16:115-121.

Medication Class ACE-I, ARB Indications to use first line Contraindications Clinical Pearls DM CKD HF or LV dysfunction with LVEF 40% Coronary artery disease Recurrent stroke prevention Bilateral renal artery stenosis Pregnancy Angioedema -SCr increase up to 30% above baseline is acceptable -Monitor for hyperkalemia, dry cough (ACE-I > ARB), angioedema -Avoid in women during childbearing years -Consider lower initial dose in elderly, renal impairment or concomitant diuretic use

Medication Class Beta Blockers Indications to use first line Contraindications Clinical Pearls HF or LV systolic dysfunction with LVEF 40% (bisoprolol, carvedilol, metoprolol succinate first line with ACE-I) Post-MI SA or AV node dysfunction Decompensated HF Severe bronchospasm Adjust doses for symptomatic bradycardia May cause exercise intolerance, sexual dysfunction, fatigue Monitor HR regularly

Medication Class Thiazide diuretics Potassium sparing diuretics Loop diuretics Indications to use first line Contraindications Clinical Pearls Hypertension Anuria -First line or in combination with an ACE-I, ARB, or CCB -Monitor Na, K, SCr -May cause hyperuricemia -- Anuria Hyperkalemia Severe renal or hepatic disease -Usually used in combination with thiazide diuretic for potassium balance -Monitor K, SCr HF, CKD Anuria -Monitor Na, K, SCr -Ethacrynic acid 25-50 mg daily may be used if sulfa allergy

Medication Class Indications to use first line Contraindications Clinical Pearls Dihydropyridine calcium channel blockers Hypertension Angina -Monitor for peripheral edema Nondiphydropyridine calcium channel blockers Atrial fibrillation Stable angina Heart block LV systolic dysfunction (EF < 40%) -Monitor heart rate -CYP450 inhibitor -Constipation with verapamil

Medication Class Indications to use first line Contraindications Clinical Pearls Aldosterone antagonists Resistant HTN HF Anuria Avoid if CrCl < 30 ml/min or K > 5 meq/l Monitor K, SCr at 3 days, 7 days, and monthly x first 3 months after initiation or titration -Gynecomastia with spironolactone Alpha-1 blockers (terazosin, doxazosin, prazosin) BPH PTSD -First dose hypotension start low dose, take at bedtime -4 th or 5 th line

Medication Class Indications to use first line Contraindications Clinical Pearls Central alpha-2 agonists (clonidine, methyldopa, guanfacine) Resistant HTN Hypertensive urgency Pregnancy Avoid in HF -De-escalate dose slowly rebound HTN, especially if taking a beta blocker -Dry mouth, orthostatic hypotension Vasodilators (hydralazine, minoxidil) Resistant HTN HTN + HF (hydralazine) -Hydralazine: drug induced lupus, tachycardia (use w/ beta-blocker) -Minoxidil: fluid retention (use with diuretic), hirsutism

Guidelines for Reference JNC 8: James PA, Oparil S, Carter BL, et al. JAMA 2014;311:507-20. KDIGO: Kidney Int 2013;5:337-414. ASH/ISH: Weber MA, Schiffrin EL, White WB, et al. J Clin Hypertens 2014;16:14-26. AHA/ACC/ASH: Rosendorff C, Lackland DT, Allison M, et al. Circulation 2015;131:e435-70. CHEP: Hackam DG, Quin RR, Ravani P, et al. Can J Cardiol 2013;29:528-42. ESH/ESC: Mancia G, Fagard R,Narkiewicz K, et al. J Hypertens 2013;31:1281-1357.

Hypertension Clinical Pearls: We re treating more than a number Emily Ashjian, PharmD, BCPS, BCACP February 2017